Our top pick for
Kenon Holdings Ltd is an utilities-regulated electric business based in the US. Kenon shares (KEN) are listed on the NYSE and all prices are listed in US Dollars. Kenon employs 124 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$40.29|
|52-week range||$19.39 - $43.96|
|50-day moving average||$41.15|
|200-day moving average||$36.33|
|Wall St. target price||$29.85|
|Dividend yield||$1.86 (4.56%)|
|Earnings per share (TTM)||$10.48|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-2.68%|
|1 month (2021-09-24)||-7.10%|
|3 months (2021-07-26)||26.06%|
|6 months (2021-04-26)||15.64%|
|1 year (2020-10-26)||60.84%|
|2 years (2019-10-25)||80.69%|
|3 years (2018-10-26)||157.77%|
|5 years (2016-10-26)||292.31%|
Valuing Kenon stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kenon's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Kenon's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Kenon shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Kenon's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $51.1 million.
The EBITDA is a measure of a Kenon's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$441.5 million|
|Operating margin TTM||1.19%|
|Gross profit TTM||$104.4 million|
|Return on assets TTM||0.13%|
|Return on equity TTM||37.73%|
|Market capitalisation||$2.2 billion|
TTM: trailing 12 months
There are currently 18,613 Kenon shares held short by investors – that's known as Kenon's "short interest". This figure is 73.1% up from 10,754 last month.
There are a few different ways that this level of interest in shorting Kenon shares can be evaluated.
Kenon's "short interest ratio" (SIR) is the quantity of Kenon shares currently shorted divided by the average quantity of Kenon shares traded daily (recently around 11489.50617284). Kenon's SIR currently stands at 1.62. In other words for every 100,000 Kenon shares traded daily on the market, roughly 1620 shares are currently held short.
However Kenon's short interest can also be evaluated against the total number of Kenon shares, or, against the total number of tradable Kenon shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kenon's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Kenon shares in existence, roughly 0 shares are currently held short) or 0.0011% of the tradable shares (for every 100,000 tradable Kenon shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kenon.
Find out more about how you can short Kenon stock.
Dividend payout ratio: 49.05% of net profits
Recently Kenon has paid out, on average, around 49.05% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 9.12% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Kenon shareholders could enjoy a 9.12% return on their shares, in the form of dividend payments. In Kenon's case, that would currently equate to about $1.86 per share.
While Kenon's payout ratio might seem fairly standard, it's worth remembering that Kenon may be investing much of the rest of its net profits in future growth.
Kenon's most recent dividend payout was on 5 May 2021. The latest dividend was paid out to all shareholders who bought their shares by 23 August 2021 (the "ex-dividend date").
Over the last 12 months, Kenon's shares have ranged in value from as little as $19.3918 up to $43.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Kenon's is 1.1062. This would suggest that Kenon's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Kenon Holdings Ltd. , through its subsidiaries, operates as an owner, developer, and operator of power generation facilities in Israel and internationally. It operates in three segments: OPC, Quantum, and ZIM. The company's power generation plants operate on natural gas and diesel with an installed capacity of approximately 610 MW. It also designs, engineers, manufactures, and sells automobiles in China. As of December 31, 2020, the company's Qoros' dealerships included 418 point of sales facilities. In addition, Kenon Holdings Ltd.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.